199 related articles for article (PubMed ID: 34104089)
1. A clinical study on plasma biomarkers for deciding the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia of premature infants.
Zhu H; Tian Y; Cheng H; Zheng Y; Wang W; Bao T; Wu R; Tian Z
Int J Med Sci; 2021; 18(12):2581-2588. PubMed ID: 34104089
[No Abstract] [Full Text] [Related]
2. Soluble E-selectin, soluble L-selectin and soluble ICAM-1 in bronchopulmonary dysplasia, and changes with dexamethasone.
Ballabh P; Kumari J; Krauss AN; Shin JJ; Jain A; Auld PA; Lesser ML; Cunningham-Rundles S
Pediatrics; 2003 Mar; 111(3):461-8. PubMed ID: 12612222
[TBL] [Abstract][Full Text] [Related]
3. Vitamin A status and postnatal dexamethasone treatment in bronchopulmonary dysplasia.
Shenai JP; Mellen BG; Chytil F
Pediatrics; 2000 Sep; 106(3):547-53. PubMed ID: 10969101
[TBL] [Abstract][Full Text] [Related]
4. Decreased neutrophil levels in bronchopulmonary dysplasia infants.
Li X; Wang Q; Luo T; Li T
Pediatr Neonatol; 2020 Dec; 61(6):637-644. PubMed ID: 32863167
[TBL] [Abstract][Full Text] [Related]
5. Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants.
Shah SS; Ohlsson A; Halliday HL; Shah VS
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD002057. PubMed ID: 29035425
[TBL] [Abstract][Full Text] [Related]
6. Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone.
Ballabh P; Simm M; Kumari J; Califano C; Aghai Z; Laborada G; Sison C; Cunningham-Rundles S
Pediatr Pulmonol; 2003 May; 35(5):392-9. PubMed ID: 12687597
[TBL] [Abstract][Full Text] [Related]
7. Delayed Dexamethasone Therapy and Neurodevelopmental Outcomes in Preterm Infants with Bronchopulmonary Dysplasia.
Lim G; Lee BS; Choi YS; Park HW; Chung ML; Choi HJ; Kim EA; Kim KS
Pediatr Neonatol; 2015 Aug; 56(4):261-7. PubMed ID: 25649722
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA expression aberration associated with bronchopulmonary dysplasia in preterm infants: a preliminary study.
Wu YT; Chen WJ; Hsieh WS; Tsao PN; Yu SL; Lai CY; Lee WC; Jeng SF
Respir Care; 2013 Sep; 58(9):1527-35. PubMed ID: 23481439
[TBL] [Abstract][Full Text] [Related]
9. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
Doyle LW; Cheong JL; Ehrenkranz RA; Halliday HL
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD001146. PubMed ID: 29063585
[TBL] [Abstract][Full Text] [Related]
10. Angiopoietin 2 concentrations in infants developing bronchopulmonary dysplasia: attenuation by dexamethasone.
Aghai ZH; Faqiri S; Saslow JG; Nakhla T; Farhath S; Kumar A; Eydelman R; Strande L; Stahl G; Leone P; Bhandari V
J Perinatol; 2008 Feb; 28(2):149-55. PubMed ID: 18033304
[TBL] [Abstract][Full Text] [Related]
11. The association of γδ-T cells with bronchopulmonary dysplasia in premature infants.
Wang YJ; Zhang XL; Liu JX; Niu M; Jin XY; Yuan EW; Shi Y; Li WL; Xu FL
Hum Immunol; 2021 Jan; 82(1):54-59. PubMed ID: 33288226
[TBL] [Abstract][Full Text] [Related]
12. [Glucocorticoide therapy in premature infants: French practices in 2006].
Autret-Leca E; Bauer S; Alberti C; Jonville-Béra AP; Aujard Y; Bensouda-Grimaldi L; Baud O
Arch Pediatr; 2009 Jul; 16(7):999-1004. PubMed ID: 19410441
[TBL] [Abstract][Full Text] [Related]
13. Early diagnostic value of C-reactive protein as an inflammatory marker for moderate-to-severe bronchopulmonary dysplasia in premature infants with birth weight less than 1500 g.
Yang Y; Li J; Mao J
Int Immunopharmacol; 2022 Feb; 103():108462. PubMed ID: 34952464
[TBL] [Abstract][Full Text] [Related]
14. Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates.
Shah SS; Ohlsson A; Halliday HL; Shah VS
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD002058. PubMed ID: 29041034
[TBL] [Abstract][Full Text] [Related]
15. NTproBNP is a useful early biomarker of bronchopulmonary dysplasia in very low birth weight infants.
Méndez-Abad P; Zafra-Rodríguez P; Lubián-López S; Benavente-Fernández I
Eur J Pediatr; 2019 May; 178(5):755-761. PubMed ID: 30820654
[TBL] [Abstract][Full Text] [Related]
16. Effect of dexamethasone on lymphocyte subpopulations in premature infants with bronchopulmonary dysplasia.
Parimi PS; Birnkrant DJ; Rao LV; Diaz G; Moore JJ
J Perinatol; 1999; 19(5):347-51. PubMed ID: 10685255
[TBL] [Abstract][Full Text] [Related]
17. Serum selenium levels of the very low birth weight premature newborn infants with bronchopulmonary dysplasia.
Peirovifar A; Gharehbaghi MM; Abdulmohammad-Zadeh H; Sadegi GH; Jouyban A
J Trace Elem Med Biol; 2013 Oct; 27(4):317-21. PubMed ID: 23791402
[TBL] [Abstract][Full Text] [Related]
18. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.
Doyle LW; Cheong JL; Ehrenkranz RA; Halliday HL
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD001145. PubMed ID: 29063594
[TBL] [Abstract][Full Text] [Related]
19. Effect of dexamethasone on leukocyte numbers and lymphocyte-blastogenic responses to mitogens in infants with bronchopulmonary dysplasia.
Moya FR; Becerra M; Leiva L; Sorensen RU
Clin Pediatr (Phila); 1993 Mar; 32(3):185-8. PubMed ID: 8453841
[No Abstract] [Full Text] [Related]
20. [Evaluation of the level of urinary cysteinyl leukotriene E4 in diagnosis of bronchopulmonary dysplasia in premature infants].
Jin R; Lu HY; Luo YY; Xu YX; Hu YH; Chen XQ
Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):703-7. PubMed ID: 27596087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
